Tirzepatide is a dual GIP and GLP-1 receptor agonist used in the treatment of type 2 diabetes, obesity, and obstructive sleep apnea. This resource reviews how the medication works, including its affinity for GIP receptors, biased agonism toward cyclic AMP, and effects on adiponectin, along with the…
Tirzepatide is a prescription peptide medication that targets two hormones involved in blood sugar control and appetite regulation. It is given by subcutaneous injection, meaning it is injected into the layer of fat beneath the skin. In the United States, it is approved for type 2 diabetes, chronic weight management, and moderate-to-severe obstructive sleep apnea in appropriate adults. It is not an over-the-counter product and should only be used under medical supervision.
The body naturally produces two important incretin hormones after meals: glucose-dependent insulinotropic polypeptide, or GIP, and glucagon-like peptide-1, or GLP-1. Both help the pancreas release insulin when blood glucose rises, and both influence how quickly food leaves the stomach and how full a person feels. GLP-1 receptor agonists have been used for years in diabetes and obesity treatment. Tirzepatide goes a step further by also acting like GIP. It is a GIP analog and a GLP-1 receptor agonist at the same time, so it engages both incretin pathways rather than only one. This dual action is part of the reason researchers and clinicians have taken a strong interest in the drug.
Tirzepatide is sold under two primary brand names in the United States. Mounjaro is used for diabetes management. Zepbound is used for weight loss and for obstructive sleep apnea treatment. The FDA approved Mounjaro for type 2 diabetes in May 2022. In November 2023, Zepbound was approved for weight management in adults with obesity or who are overweight with at least one weight-related condition. Then in December 2024, Zepbound received approval for moderate-to-severe obstructive sleep apnea. Obstructive sleep apnea is a condition in which the upper airway repeatedly collapses during sleep, causing pauses in breathing. The approval expanded the population of people who may be offered the medicine. Regulatory status varies by country, so these approvals do not automatically apply to all regions.
Tirzepatide does not bind to its two target receptors equally. It has a greater affinity for the GIP receptor than for the GLP-1 receptor. GIP receptor activation appears to contribute to insulin release and fat metabolism, while GLP-1 receptor activation contributes to glucose-dependent insulin secretion, slower gastric emptying, and appetite suppression. The drug displays biased agonism toward cyclic AMP generation. In pharmacology, biased agonism means that a drug activates some signaling pathways downstream of a receptor more strongly than others. Cyclic AMP, or cAMP, is a second messenger inside cells that promotes insulin secretion from beta cells. This may explain why tirzepatide has produced superior glucose control in clinical comparisons with selective GLP-1 agonists.
Adipose tissue also responds to tirzepatide. Research has reported that adiponectin levels increase by up to 26% after 26 weeks at the 10 mg dose. Adiponectin is a hormone released by fat cells that supports insulin sensitivity and has anti-inflammatory effects. Higher adiponectin is generally associated with improved metabolic health, which may be one mechanism underlying the drug's benefits beyond weight loss.
The weight loss seen in clinical trials is substantial. In a trial lasting 72 weeks, the 5 mg dose produced approximately 15% weight loss, the 10 mg dose produced approximately 19.5%, and the 15 mg dose produced approximately 20.9%. These results are expressed as average total body weight reduction and are markedly higher than what has typically been seen with older GLP-1 receptor agonists. Not every patient responds identically, and some people lose much more or much less weight. The dose-dependent pattern suggests that higher doses increase effectiveness, although they also increase side effects.
A three-year study reported in 2024 examined tirzepatide in people with prediabetes and overweight or obesity. Prediabetes means blood sugar levels are higher than normal but not high enough to meet the definition of type 2 diabetes. In that study, treatment reduced the risk of developing type 2 diabetes by 94% compared with placebo. This is a striking reduction, and it aligns with the drug's ability to improve glucose control and promote weight loss. The finding adds longer-term evidence about the potential of tirzepatide in people who have not yet developed diabetes.
The most common side effects are nausea, vomiting, diarrhea, decreased appetite, constipation, upper abdominal discomfort, and abdominal pain. These effects are familiar to anyone who has used GLP-1 based therapies. They often occur when treatment starts or when the dose is increased. In clinical trials, more people stopped taking the drug as the dose increased. Discontinuation rates were 25% for people on the 15 mg dose compared with 5.1% for people on the 5 mg dose. That difference is an important reminder that the highest dose is not the best dose for every patient. Dose selection should be guided by a clinician and adjusted based on tolerability and treatment goals.
Tirzepatide is a synthetic 39 amino acid peptide. The manufacturing approach first patented by Eli Lilly in 2016 uses solid-phase peptide synthesis. In this process, the peptide chain is assembled step by step on a solid resin support, with amino acids added in sequence and then cleaved and purified. The molecule includes a C20 fatty diacid, a 20 carbon dicarboxylic acid chain, attached to the peptide. This fatty acid modification improves cellular uptake and protects the peptide from rapid metabolism. It allows the drug to bind to albumin in the bloodstream, which slows its clearance. The result is a half-life of approximately 5 days. In pharmacokinetics, half-life is the time it takes for the concentration of a drug in the body to drop by half. A half-life of about 5 days is long enough to support weekly dosing, which is far more convenient than daily injections.
Treatment with tirzepatide does not permanently reset the body's weight set point. Once the drug is discontinued, body weight tends to return. Clinical data show that within one year after stopping treatment, patients regain more than half of the weight they lost. Most patients return to their baseline weight within approximately 18 months. This pattern is consistent with other incretin-based weight loss therapies and with the view that obesity is a chronic, relapsing condition. It also underscores the importance of continued treatment or a long-term maintenance plan for people who use this medication for weight management.
Mounjaro and Zepbound are brand-name, FDA-approved products. In some situations, people may encounter compounded versions of tirzepatide. Compounded drugs are not FDA-approved and have not been reviewed by the FDA for safety, effectiveness, or quality. The regulatory status of compounded peptide products can vary, and there have been reports of counterfeit and substandard products in the market. People should obtain tirzepatide from licensed prescribers and regulated pharmacies. The medicine should not be shared with others, and it should not be purchased from unverified online sellers.
The available evidence shows clearly that tirzepatide can produce major weight loss, improve glucose control in type 2 diabetes, reduce the progression from prediabetes to diabetes, and improve obstructive sleep apnea in appropriate patients. The evidence also shows that side effects are common, particularly at higher doses, and that benefits largely disappear after discontinuation. What remains less clear is how different patients will respond over many years, whether intermittent dosing schedules can preserve benefits with fewer side effects, and how the drug compares with surgical weight loss options over the long run. Ongoing studies will continue to refine the picture.
This resource is provided for educational purposes only. It does not constitute medical advice, product endorsement, or a treatment recommendation. Anyone considering tirzepatide should consult a qualified health care provider and review the official prescribing information. Discussion of approvals applies primarily to the United States and may not reflect the regulatory status in other countries.